Why Seagen Stock Is Trading Higher During Monday's Session


Seagen Inc SGEN shares are trading higher by 4.79% to $129.94 by after the company announced results from the Phase 2 clinical trial of ADCETRIS with novel immunotherapy combination in patients with advanced- and early-stage classical Hodgkin Lymphoma.

What Happened?

Seagen says results demonstrated a complete response (CR) rate of 88% and an overall response rate (ORR) of 93% in patients with advanced-stage disease (Part B), and a CR rate of 92% and an ORR of 95% in patients with early-stage disease (Part C).

The company added that the data showed that the combination was well-tolerated, with no new safety signals observed.

See Also: Why KWESST Micro Systems Shares Are Skyrocketing

"We are encouraged that ADCETRIS in combination with the immunotherapy nivolumab and standard chemotherapy agents showed promising efficacy and safety as a first-line treatment in patients with early- and advanced-stage classical Hodgkin lymphoma," said Marjorie Green, M.D., Senior Vice President and Head of Late-Stage Development at Seagen.

"These agents with complementary mechanisms of action warrant further investigation as a potential frontline treatment option for patients with Hodgkin lymphoma."

According to data from Benzinga Pro, Seagen has a 52-week high of $183.00 and a 52-week low of $105.43.

Market News and Data brought to you by Benzinga APIs
Posted In: MoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!